The drug is manufactured by ALZA Corporation or Janssen-Cilag Manufacturing, LLC. It is marketed and distributed by Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Invega belongs to a group of medications called atypical (or second-generation)
antipsychotic medications. It is not entirely known how it works for the treatment of schizophrenia. However, it is known that the drug blocks or lessens the effects of several chemicals in the brain. These brain chemicals (such as dopamine and serotonin) may be elevated in people with schizophrenia.
Invega is not a cure for schizophrenia or schizoaffective disorder. It only helps to control symptoms
(see Symptoms of Schizophrenia).
In previous clinical studies of Invega for the treatment of schizophrenia, people taking it experienced improvements in their schizophrenia symptoms (including hallucinations and suspiciousness), compared to those not taking it.
Longer studies also showed that Invega can help prevent hospitalization due to schizophrenia and can help symptoms from returning.